Key result
Bromocriptine therapy resolves neuroleptic malignant syndrome following antipsychotic treatment for cycloserine-induced psychosis.
Case Report (n=1)
Treatment of cycloserine-induced psychosis with antipsychotics can lead to severe neurological adverse effects such as neuroleptic malignant syndrome, which requires prompt withdrawal and management.
May warrant caution prescribing antipsychotics for cycloserine psychosis; single case leaves open safer management options in MDR-TB.
A 33-year-old multidrug-resistant tuberculosis female patient diagnosed as cycloserine-induced psychosis developed several neuroleptic side effects such as extrapyramidal reaction, neuroleptic malignant syndrome, and drug-induced parkinsonism while she was being treated with initially haloperidol and then olanzapine over a period of 2 months. Patient's antipsychotic medications were withdrawn, and treatment with bromocriptine showed prompt recovery. The multiple neurological adverse effects which the patient developed had implications on the management of the complications as well as her illness.
No takes yet. Share an insight, caveat, or question.
Kate et al. (2015) conducted a case report in Multidrug-resistant tuberculosis, cycloserine-induced psychosis, neuroleptic malignant syndrome (n=1). Cycloserine and antipsychotics (haloperidol, olanzapine) was evaluated on Development and resolution of neuroleptic malignant syndrome. A 33-year-old female with multidrug-resistant tuberculosis developed cycloserine-induced psychosis and subsequently suffered from neuroleptic malignant syndrome following antipsychotic treatment, which resolved upon drug withdrawal and bromocriptine therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: